Format

Send to

Choose Destination
See comment in PubMed Commons below
MAbs. 2012 Mar-Apr;4(2):182-97. doi: 10.4161/mabs.4.2.19000. Epub 2012 Mar 1.

Dual targeting strategies with bispecific antibodies.

Author information

1
Institut für Zellbiologie und Immunologie; Universität Stuttgart; Stuttgart, Germany.

Abstract

Monoclonal antibodies are widely used for the treatment of cancer, inflammatory and infectious diseases and other disorders. Most of the marketed antibodies are monospecific and therefore capable of interacting and interfering with a single target. However, complex diseases are often multifactorial in nature, and involve redundant or synergistic action of disease mediators or upregulation of different receptors, including crosstalk between their signaling networks. Consequently, blockade of multiple, different pathological factors and pathways may result in improved therapeutic efficacy. This result can be achieved by combining different drugs, or use of the dual targeting strategies applying bispecific antibodies that have emerged as an alternative to combination therapy. This review discusses the various dual targeting strategies for which bispecific antibodies have been developed and provides an overview of the established bispecific antibody formats.

KEYWORDS:

allergic diseases; bispecific antibodies; cancer therapy; dual retargeting; dual targeting; inflammatory diseases

PMID:
22453100
PMCID:
PMC3361654
DOI:
10.4161/mabs.4.2.19000
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis Icon for PubMed Central
    Loading ...
    Support Center